Myriad Genetics (MYGN) Receivables - Other (2010 - 2021)

Myriad Genetics (MYGN) has 12 years of Receivables - Other data on file, last reported at $2.4 million in Q1 2021.

• Receivables - Other for Q1 2021 came in at $2.4 million, down 4.0% year-over-year; the trailing twelve-month figure through Mar 2021 was $2.4 million (down 4.0% YoY), and the FY2020 annual result was $2.0 million, changed N/A from the prior year.
• Receivables - Other climbed to $2.4 million in Q1 2021 per MYGN's latest filing, from $2.0 million in the prior quarter.
• Over five years, Receivables - Other peaked at $6.9 million in Q3 2017 and troughed at $2.0 million in Q3 2020.
• A 5-year average of $4.1 million and a median of $4.3 million in 2018 frame the typical range for Receivables - Other.
• The sharpest annual moves came in 2017 and 2020: Receivables - Other surged 72.73% in 2017, then sank 58.33% in 2020.
• A 5-year view of Receivables - Other shows it stood at $6.0 million in 2017, then declined by 1.67% to $5.9 million in 2018, then plunged by 40.68% to $3.5 million in 2019, then tumbled by 42.86% to $2.0 million in 2020, then increased by 20.0% to $2.4 million in 2021.
• Business Quant data shows MYGN's Receivables - Other at $2.4 million in Q1 2021, $2.0 million in Q4 2020, and $2.0 million in Q3 2020.